MV010/MV004, in cancer immunotherapy
• Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models.
• Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models.
